Rossari Biotech Limited has announced its consolidated unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a total income from operations of ₹5,816.80 crore for the quarter. Net profit after tax for the period stood at ₹327.74 crore, and total comprehensive income was ₹326.00 crore.

For the nine months ended December 31, 2025, the total income from operations was ₹17,051.00 crore. The net profit after tax for the nine-month period was ₹1,032.46 crore, with total comprehensive income at ₹1,027.02 crore.

The company's equity share capital remains ₹110.76 crore. Earnings per share (EPS) for the quarter were ₹5.92 (basic) and ₹5.91 (diluted), not annualized. The consolidated financial results were reviewed by the Audit Committee and approved by the Board of Directors on January 17, 2026. The statutory auditors have also carried out a review of the interim financial results.